KV

Kenvue Inc.

KVUEConsumer DefensiveNASDAQ

Household & Personal Products · Last scanned Oct 24, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$15.12B
-2.1% YoY
Net Income
$1.47B
+42.7% YoY
EBITDA
$2.99B
+21.0% YoY
Free Cash Flow
$1.91B

Scan Results

Daily timeframe
8 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 14▲ Above MA150+0.2% from MA150, price crossed above
Oct 13▲ Above MA150+0.6% from MA150, price crossed above
About Kenvue Inc.

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. Valued at $37.59B, KVUE is a large-cap name in its sector. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health.

Where KVUE stands vs its 150-day and 200-day moving averages

As of the October 14, 2026 close, KVUE finished 0.17% above its 150-day moving average ($17.73) and 1.02% above its 200-day moving average ($17.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is KVUE overbought or oversold?

At the October 14, 2026 close, KVUE's RSI(14) was 52.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$37.59B
P/E (TTM)22.76
Fwd P/E15.79
EPS$0.86
Beta0.45
52W Change+30.5%
Dividend Yield4.29%
ROE15.6%
Analysis

On the balance sheet, KVUE has $1.11B in cash with $8.61B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $1.91B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 15.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $14.95B (2022) to $15.12B (2025).

The relatively low beta of 0.45 suggests KVUE is a less volatile holding compared to the broader index. Kenvue Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kenvue Inc. and its sector.

Links
More Consumer Defensive stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms